Loading...
OTCMALPMY
Market cap17bUSD
Dec 23, Last price  
9.64USD
1D
-1.53%
1Q
-19.60%
Jan 2017
-30.45%
Name

Astellas Pharma Inc

Chart & Performance

D1W1MN
OTCM:ALPMY chart
P/E
159.04
P/S
1.69
EPS
9.52
Div Yield, %
675.99%
Shrs. gr., 5y
-1.43%
Rev. gr., 5y
4.19%
Revenues
1.60t
+5.60%
447,051,000,000879,362,000,000920,624,000,000972,586,000,000965,698,000,000974,877,000,000953,947,000,000969,387,000,0001,005,611,000,0001,139,909,000,0001,247,259,000,0001,372,706,000,0001,311,665,000,0001,300,316,000,0001,306,348,000,0001,300,843,000,0001,249,528,000,0001,296,163,000,0001,518,619,000,0001,603,672,000,000
Net income
17.05b
-82.73%
33,717,000,000103,659,000,000131,286,000,000177,438,000,000170,986,000,000122,257,000,00067,650,000,00078,230,000,00082,851,000,00090,874,000,000135,856,000,000193,687,000,000218,701,000,000164,679,000,000222,265,000,000195,411,000,000120,589,000,000124,086,000,00098,714,000,00017,045,000,000
CFO
172.48b
-47.38%
48,588,000,000140,151,000,000127,930,000,000186,930,000,000197,791,000,000150,130,000,000100,639,000,000172,675,000,000144,152,000,000214,257,000,000187,686,000,000313,737,000,000235,612,000,000312,614,000,000258,630,000,000221,998,000,000306,843,000,000257,444,000,000327,767,000,000172,475,000,000
Dividend
Mar 27, 20240.19799 USD/sh
Earnings
Feb 03, 2025

Profile

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
URL
https://www.astellas.com/
IPO date
May 16, 1949
Employees
14,484
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
1,603,672,000
5.60%
1,518,619,000
17.16%
1,296,163,000
3.73%
Cost of revenue
1,425,602,000
1,194,753,000
1,047,859,000
Unusual Expense (Income)
NOPBT
178,070,000
323,866,000
248,304,000
NOPBT Margin
11.10%
21.33%
19.16%
Operating Taxes
7,924,000
33,647,000
32,800,000
Tax Rate
4.45%
10.39%
13.21%
NOPAT
170,146,000
290,219,000
215,504,000
Net income
17,045,000
-82.73%
98,714,000
-20.45%
124,086,000
2.90%
Dividends
(116,653,000)
(100,355,000)
(85,236,000)
Dividend yield
3.94%
2.92%
2.41%
Proceeds from repurchase of equity
(10,735,000)
(42,051,000)
(68,532,000)
BB yield
0.36%
1.22%
1.94%
Debt
Debt current
487,222,000
88,546,000
157,730,000
Long-term debt
589,250,000
115,678,000
55,690,000
Deferred revenue
121,279,000
138,943,000
Other long-term liabilities
118,050,000
40,986,000
39,234,000
Net debt
596,364,000
(337,428,000)
(265,069,000)
Cash flow
Cash from operating activities
172,475,000
327,767,000
257,444,000
CAPEX
(38,056,000)
(88,541,000)
(76,448,000)
Cash from investing activities
(845,802,000)
(84,500,000)
(62,413,000)
Cash from financing activities
614,060,000
(195,623,000)
(216,298,000)
FCF
79,650,000
313,352,000
239,322,000
Balance
Cash
335,687,000
396,624,000
337,283,000
Long term investments
144,421,000
145,028,000
141,206,000
Excess cash
399,924,400
465,721,050
413,680,850
Stockholders' equity
1,445,701,000
2,519,113,000
2,507,570,000
Invested Capital
2,319,829,600
1,342,123,950
1,350,822,150
ROIC
9.29%
21.55%
15.81%
ROCE
6.43%
17.85%
14.03%
EV
Common stock shares outstanding
1,799,660
1,825,061
1,850,602
Price
1,643.50
-12.72%
1,883.00
-1.47%
1,911.00
12.28%
Market cap
2,957,741,210
-13.93%
3,436,589,863
-2.83%
3,536,500,422
11.82%
EV
3,554,105,210
4,266,476,863
4,484,227,422
EBITDA
335,910,000
429,604,000
327,988,000
EV/EBITDA
10.58
9.93
13.67
Interest
12,005,000
8,779,000
4,949,000
Interest/NOPBT
6.74%
2.71%
1.99%